Alliance Pharma - quality AIM stock to buy
Specialty pharmaceutical company Alliance Pharma (APH) has today announced an $11.5 million (£7.5 million) acquisition of all existing rights to the ‘Syntometrine’ drug from industry major Novartis. This is part of its strategy of buying in “orphan” brands from majors which it can then monetize by flogging through its existing sales infrastructure.
